Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Chief Medical Officer | March 03, 2025 | March 05, 2025 |
| Passage BIO, Inc.PASG · Entity 7829 | Chief Medical Officer | March 15, 2021 | March 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 332,977 |
Reported balance
After 2025-03-03 transaction · row 1
1 source rowRow 1 · 2025-03-03 · Sale · Disposed 16,306 · Balance 332,977 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.4673 to $1.4686. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.4673 to $1.4686. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request.
Passage BIO, Inc.
Report date March 15, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-03-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-15 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2021-03-15 · Sale · Disposed 8,383 · Balance 1,617 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Row 3 · 2021-03-15 · Sale · Disposed 1,617 · Balance 0 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2029-10-23 | Direct | 300,821 |
Reported balance
After 2021-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-15 · Exercise / conversion · Disposed 10,000 · Balance 300,821 F4: The option vests as to 25% of the total shares on August 20, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 20, 2023 subject to the reporting person's provision of service to the issuer on each vesting date. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4: The option vests as to 25% of the total shares on August 20, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 20, 2023 subject to the reporting person's provision of service to the issuer on each vesting date. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 16:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 16,306 | $1.47 | $23,927.42 |
DisclosureSEC source: 0000950170-25-033520 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,977 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.4673 to $1.4686. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 17:40 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 14,892 | $2.52 | $37,518.90 |
DisclosureSEC source: 0000950170-24-132910 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,283 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.5194 to $2.5197. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 16:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 184,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111419 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,175 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2024. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 16:15 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 8,478 | $4.88 | $41,385.36 |
DisclosureSEC source: 0000950170-24-103406 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,795 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8814 to $4.8820. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 18:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 8,040 | $4.80 | $38,581.55 |
DisclosureSEC source: 0000950170-24-068939 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,273 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.7984 to $4.7987. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 18:00 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 6,001 | $6.92 | $41,553.92 |
DisclosureSEC source: 0000950170-24-026429 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,313 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.9238 to $6.9247. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 18:30 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 5,035 | $5.56 | $27,994.60 |
DisclosureSEC source: 0000950170-23-068618 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,314 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 18:12 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0000950170-23-051706 · ownership.xml · derivative · entry 2 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2023. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 18:12 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 108,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-051706 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,349 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on December 1, 2023. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 19:16 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,771 | $5.19 | $14,393.13 |
DisclosureSEC source: 0000950170-23-046833 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,349 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.1939 to $5.1943. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 18:50 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,617 | $6.90 | $18,066.98 |
DisclosureSEC source: 0000950170-23-026475 · ownership.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,120 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 20:56 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 3,238 | $8.32 | $26,933.36 |
DisclosureSEC source: 0001209191-23-016091 · doc4.xml · nonDerivative · entry 2 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,737 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| December 02, 2022 Filed Mar 3, 2023 20:56 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,145 | $8.71 | $18,679.09 |
DisclosureSEC source: 0001209191-23-016091 · doc4.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,975 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 20:03 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 13,365 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-22-052566 · doc4.xml · derivative · entry 2 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,365 Underlying: Common Stock · 13,365 shares Expires 2032-10-01 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on November 1, 2022. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 20:03 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 20,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052566 · doc4.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,120 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on March 1, 2023. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:17 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 2,177 | $10.62 | $23,120.18 |
DisclosureSEC source: 0001209191-22-049006 · doc4.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,073 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:53 UTC | Alector, Inc. ALEC · Entity 6051 | GrantEmployee Stock Option (right to buy) · Derivative | 369,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001209191-22-032935 · doc4.xml · derivative · entry 2 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,000 Underlying: Common Stock · 369,000 shares Expires 2032-05-27 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 23, 2022. Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:53 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 92,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032935 · doc4.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 12 equal quarterly installments beginning on September 1, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-21-021616 · doc4.xml · derivative · entry 4 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,821 Underlying: Common Stock · 10,000 shares Expires 2029-10-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 25% of the total shares on August 20, 2020 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 20, 2023 subject to the reporting person's provision of service to the issuer on each vesting date. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 1,617 | $21.86 | $35,350.21 |
DisclosureSEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 3 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 8,383 | $20.95 | $175,662.41 |
DisclosureSEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 2 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.60 to $21.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:12 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 10,000 | $8.07 | $80,700.00 |
DisclosureSEC source: 0001209191-21-021616 · doc4.xml · nonDerivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 19:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $21.85 | $0.00 |
DisclosureSEC source: 0001209191-21-012160 · doc4.xml · derivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 17:49 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (Right to Buy) · Derivative | 74,311 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014688 · doc4.xml · derivative · entry 1 Romano Gary · CIK 0001799779 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,311 Underlying: Common Stock · 74,311 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 27, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 27, 2024, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.